Betta Pharmaceuticals
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (33)
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Started: 5/24/2022
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Started: 3/28/2023
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
Started: 12/1/2012
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Started: 3/1/2010
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
Started: 2/1/2009
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Started: 9/1/2025
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
Started: 12/24/2019
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
Started: 3/31/2025
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Started: 8/12/2021
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Started: 1/1/2014
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
Started: 5/1/2013
Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Started: 11/29/2017
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Started: 6/1/2009
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Started: 1/31/2026
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Started: 9/24/2021
A Study of BPI-460372 in Advanced Solid Tumor Patients
Started: 4/24/2023
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Started: 8/29/2022
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Started: 2/12/2026
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
Started: 7/18/2019
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
Started: 12/13/2024
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
Started: 7/1/2024
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Started: 9/1/2023
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
Started: 3/6/2017
A Food-Effect Study of BPI-16350 in Healthy Subjects
Started: 4/15/2022
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
Started: 8/11/2015
A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
Started: 3/12/2018
Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers
Started: 6/11/2018
Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
Started: 12/29/2016
Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Started: 9/17/2016
Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
Started: 11/26/2015
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Started: 12/1/2011
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Started: 2/1/2013
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
Started: 9/1/2011